Seres Therapeutics, Inc. (MCRB) Receives Consensus Rating of “Buy” from Brokerages
Seres Therapeutics, Inc. (NASDAQ:MCRB) has received a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $18.25.
A number of analysts recently commented on MCRB shares. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 5th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. Cantor Fitzgerald set a $16.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. Finally, BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th.
WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/18/seres-therapeutics-inc-mcrb-receives-consensus-rating-of-buy-from-brokerages.html.
A number of institutional investors have recently made changes to their positions in MCRB. Voya Investment Management LLC bought a new position in shares of Seres Therapeutics during the second quarter worth $114,000. American International Group Inc. raised its position in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Seres Therapeutics during the first quarter worth $136,000. Advisor Group Inc. raised its position in shares of Seres Therapeutics by 100.7% in the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock worth $160,000 after buying an additional 7,050 shares during the last quarter. Finally, State of Wisconsin Investment Board bought a new position in shares of Seres Therapeutics during the second quarter worth $169,000. 75.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Seres Therapeutics (NASDAQ MCRB) opened at 13.33 on Friday. The stock has a 50 day moving average price of $12.73 and a 200 day moving average price of $10.79. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09. The firm’s market cap is $540.02 million.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The firm had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. During the same quarter in the prior year, the company earned ($0.70) EPS. Seres Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts expect that Seres Therapeutics will post ($2.48) EPS for the current year.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.